^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    PDE3 inhibitor

    Related drugs:
    2d
    A Phase II Clinical Trial on the Efficacy and Safety of TQC3721 Inhalation Powder (clinicaltrials.gov)
    P2, N=195, Active, not recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Recruiting --> Active, not recruiting
    Enrollment closed
    14d
    MIF-Induced CD74+ Microglia and Macrophages Promote Progression of Brain Metastasis and are Clinically Relevant Across Central Nervous System Disorders. (PubMed, Cancer Res)
    The brain-penetrant drug ibudilast, which prevents the binding of MIF to CD74, decreased brain metastasis in experimental models in vivo and in patient-derived organotypic cultures ex vivo in a primary tumor-agnostic manner. These findings suggest that MIF/CD74-induced reprogramming of myeloid cells in brain disorders is a vulnerability that could be exploited therapeutically against brain metastases, and possibly other brain disorders.
    Journal
    |
    CD74 (CD74 Molecule) • IFNG (Interferon, gamma)
    |
    Eyevinal (ibudilast)
    14d
    TNX-103-07: LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2 (2025-522475-28-00)
    P2/3, N=116, Not yet recruiting, Tenax Therapeutics Inc.
    New P2/3 trial
    23d
    LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2 (clinicaltrials.gov)
    P3, N=540, Recruiting, Tenax Therapeutics, Inc. | Initiation date: Dec 2025 --> Mar 2026
    Trial initiation date
    28d
    Evaluation of the Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (clinicaltrials.gov)
    P3, N=800, Not yet recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    New P3 trial
    30d
    Effect of Cilostazol in Promoting Hematoma Clearance After Intracerebral Hemorrhage (clinicaltrials.gov)
    P2, N=100, Recruiting, National Taiwan University Hospital | Not yet recruiting --> Recruiting | Trial primary completion date: May 2027 --> Jan 2027
    Enrollment open • Trial primary completion date
    1m
    COMBAT-ALS: Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS (clinicaltrials.gov)
    P2/3, N=234, Active, not recruiting, MediciNova | Trial completion date: Dec 2026 --> Apr 2028 | Trial primary completion date: Dec 2025 --> Apr 2027
    Trial completion date • Trial primary completion date
    |
    Eyevinal (ibudilast)
    1m
    A Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics for a Single Dose of HRS-9821 Powder for Inhalation and Inhalation Suspension Administered in Healthy Subjects and Multiple Doses in Patients With COPD. (clinicaltrials.gov)
    P1, N=160, Recruiting, Guangdong Hengrui Pharmaceutical Co., Ltd | N=82 --> 160 | Trial completion date: Jan 2026 --> Dec 2026 | Trial primary completion date: Jan 2026 --> Dec 2026
    Enrollment change • Trial completion date • Trial primary completion date
    1m
    RECLAIM: Recovering From COVID-19 Lingering Symptoms Adaptive Integrative Medicine (clinicaltrials.gov)
    P2/3, N=460, Completed, University Health Network, Toronto | Suspended --> Completed
    Trial completion
    |
    Eyevinal (ibudilast)
    2ms
    Long-Term Safety and Efficacy of HSK39004 Dry Powder Inhaler in COPD: A Multicenter, Single-Arm, Open-Label Study (clinicaltrials.gov)
    P2, N=300, Not yet recruiting, Haisco Pharmaceutical Group Co., Ltd.
    New P2 trial
    2ms
    MN-001 in Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus, and Hypertriglyceridemia (clinicaltrials.gov)
    P2, N=40, Active, not recruiting, MediciNova | Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2025 --> Dec 2026
    Enrollment closed • Trial primary completion date
    2ms
    Cilostazol for Preventing Delayed Cerebral Ischemia in Aneurysmal Subarachnoid Hemorrhage: A Prospective, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial (ChiCTR2500112673)
    P=N/A, N=316, Not yet recruiting, Beijing Tiantan Hospital, Capital Medical University; Beijing Tiantan Hospital, Capital Medical University
    New trial